Skip to main content
Erschienen in: World Journal of Surgery 6/2017

24.01.2017 | Original Scientific Report

Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer

verfasst von: Yuta Ibuki, Yoichi Hamai, Jun Hihara, Manabu Emi, Junya Taomoto, Takaoki Furukawa, Ichiko Yamakita, Tomoaki Kurokawa, Morihito Okada

Erschienen in: World Journal of Surgery | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Elevated preoperative serum C-reactive protein (CRP) levels are reportedly associated with a poor prognosis for patients with various types of malignant tumors. However, the impact of postoperative CRP levels on the prognosis of patients with esophageal cancer remains unknown. The present study aims to clarify the prognostic significance of postoperative CRP levels on the survival of patients with esophageal cancer.

Methods

We reviewed the records of consecutive 202 patients with thoracic esophageal squamous cell carcinoma who underwent transthoracic esophagectomy. We measured serum CRP levels on postoperative days (PODs) 1, 2, 3, 5 and 7 and evaluated the relationships between postoperative CRP levels and survival.

Results

The findings of Cox regression analyses suggested that elevated CRP levels on POD 3, 5 and 7 were associated with poor recurrence-free survival (RFS). We divided CRP levels on POD 7 into three tertiles and found that RFS could be clearly stratified, being the poorest (p < 0.001) in the highest tertile (high CRP). The trend was similar even in patients with or without infectious complications and with or without advanced pathological stage. Multivariate analysis showed that pathologically advanced stage (Hazard ratio [HR], 5.14; 95% confidence interval [CI] 2.67–9.87; p < 0.001) and high CRP (HR, 2.27; 95% CI 1.3–3.96; p = 0.004) were independent predictors of RFS.

Conclusion

Postoperative CRP levels could predict the prognosis of patients with esophageal cancer. We propose that the clinical course of postoperative CRP level should be carefully monitored as a predictor of survival.
Literatur
1.
Zurück zum Zitat Shimada H, Nabeya Y, Okazumi S et al (2003) Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 133:486–494CrossRefPubMed Shimada H, Nabeya Y, Okazumi S et al (2003) Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 133:486–494CrossRefPubMed
2.
Zurück zum Zitat Munck-Wikland E, Kuylenstierna R, Wahren B et al (1988) Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 62:2281–2286CrossRefPubMed Munck-Wikland E, Kuylenstierna R, Wahren B et al (1988) Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 62:2281–2286CrossRefPubMed
3.
Zurück zum Zitat Brockmann JG, St Nottberg H, Glodny B et al (2000) CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 6:4249–4252PubMed Brockmann JG, St Nottberg H, Glodny B et al (2000) CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 6:4249–4252PubMed
4.
Zurück zum Zitat Alifano M, Falcoz PE, Seegers V et al (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142:1161–1167CrossRefPubMed Alifano M, Falcoz PE, Seegers V et al (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142:1161–1167CrossRefPubMed
5.
Zurück zum Zitat Baba H, Kuwabara K, Ishiguro T et al (2013) C-reactive protein as a significant prognostic factor for stage IV gastric cancer patients. Anticancer Res 33:5591–5595PubMed Baba H, Kuwabara K, Ishiguro T et al (2013) C-reactive protein as a significant prognostic factor for stage IV gastric cancer patients. Anticancer Res 33:5591–5595PubMed
6.
Zurück zum Zitat Jang JW, Oh BS, Kwon JH et al (2012) Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 60:686–693CrossRefPubMed Jang JW, Oh BS, Kwon JH et al (2012) Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 60:686–693CrossRefPubMed
7.
Zurück zum Zitat Szkandera J, Stotz M, Absenger G et al (2014) Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 110:183–188CrossRefPubMed Szkandera J, Stotz M, Absenger G et al (2014) Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 110:183–188CrossRefPubMed
8.
Zurück zum Zitat Hu Q, Gou Y, Sun C et al (2014) The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol 32(50):e1–e8 Hu Q, Gou Y, Sun C et al (2014) The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol 32(50):e1–e8
9.
Zurück zum Zitat Nozoe T, Saeki H, Sugimachi K (2001) Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 182:197–201CrossRefPubMed Nozoe T, Saeki H, Sugimachi K (2001) Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 182:197–201CrossRefPubMed
10.
Zurück zum Zitat Ikeda M, Natsugoe S, Ueno S et al (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238:197–202PubMedPubMedCentral Ikeda M, Natsugoe S, Ueno S et al (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238:197–202PubMedPubMedCentral
11.
Zurück zum Zitat Shimada H, Nabeya Y, Okazumi S et al (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83:248–252CrossRefPubMed Shimada H, Nabeya Y, Okazumi S et al (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83:248–252CrossRefPubMed
12.
Zurück zum Zitat Gockel I, Dirksen K, Messow CM et al (2006) Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 12:3746–3750CrossRefPubMedPubMedCentral Gockel I, Dirksen K, Messow CM et al (2006) Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 12:3746–3750CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Wang CY, Hsieh MJ, Chiu YC et al (2009) Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 92:270–275CrossRefPubMed Wang CY, Hsieh MJ, Chiu YC et al (2009) Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 92:270–275CrossRefPubMed
14.
Zurück zum Zitat Guillem P, Triboulet JP (2005) Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18:146–150CrossRefPubMed Guillem P, Triboulet JP (2005) Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18:146–150CrossRefPubMed
15.
Zurück zum Zitat Zingg U, Forberger J, Rajcic B et al (2010) Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg 14:462–469CrossRefPubMed Zingg U, Forberger J, Rajcic B et al (2010) Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg 14:462–469CrossRefPubMed
16.
Zurück zum Zitat Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38–52CrossRefPubMed Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38–52CrossRefPubMed
17.
Zurück zum Zitat Keibel A, Singh V, Sharma MC (2009) Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 15:1949–1955CrossRefPubMed Keibel A, Singh V, Sharma MC (2009) Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 15:1949–1955CrossRefPubMed
18.
Zurück zum Zitat Hirai T, Yoshimoto A, Iwata T et al (1997) Enhancing effect of thoraco-laparotomy on liver metastasis and the role played by active oxygens in its mechanism. Surg Today 27:1040–1045CrossRefPubMed Hirai T, Yoshimoto A, Iwata T et al (1997) Enhancing effect of thoraco-laparotomy on liver metastasis and the role played by active oxygens in its mechanism. Surg Today 27:1040–1045CrossRefPubMed
19.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind CH (2009) TNM classification of malignant tumours, 7th edn. Wiley, Hoboken Sobin LH, Gospodarowicz MK, Wittekind CH (2009) TNM classification of malignant tumours, 7th edn. Wiley, Hoboken
20.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Aarden LA, De Groot ER, Schaap OL et al (1987) Production of hybridoma growth factor by human monocytes. Eur J Immunol 17:1411–1416CrossRefPubMed Aarden LA, De Groot ER, Schaap OL et al (1987) Production of hybridoma growth factor by human monocytes. Eur J Immunol 17:1411–1416CrossRefPubMed
22.
Zurück zum Zitat Sironi M, Breviario F, Proserpio P et al (1989) IL-1 stimulates IL-6 production in endothelial cells. J Immunol 142:549–553PubMed Sironi M, Breviario F, Proserpio P et al (1989) IL-1 stimulates IL-6 production in endothelial cells. J Immunol 142:549–553PubMed
23.
Zurück zum Zitat Shiba H, Furukawa K, Fujiwara Y et al (2013) Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma. Anticancer Res 33:705–709PubMed Shiba H, Furukawa K, Fujiwara Y et al (2013) Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma. Anticancer Res 33:705–709PubMed
24.
Zurück zum Zitat Johnson TV, Abbasi A, Owen-Smith A et al (2010) Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 76(766):e1–e5 Johnson TV, Abbasi A, Owen-Smith A et al (2010) Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 76(766):e1–e5
25.
Zurück zum Zitat Ito K, Yoshii H, Sato A et al (2011) Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol 186:430–435CrossRefPubMed Ito K, Yoshii H, Sato A et al (2011) Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol 186:430–435CrossRefPubMed
26.
Zurück zum Zitat Chen MF, Chen PT, Lu MS et al (2013) IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. doi:10.1186/1476-4598-12-26 Chen MF, Chen PT, Lu MS et al (2013) IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. doi:10.​1186/​1476-4598-12-26
27.
Zurück zum Zitat Nozoe T, Korenaga D, Futatsugi M et al (2003) Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus—significance as a tumor marker. Cancer Lett 192:89–95CrossRefPubMed Nozoe T, Korenaga D, Futatsugi M et al (2003) Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus—significance as a tumor marker. Cancer Lett 192:89–95CrossRefPubMed
28.
Zurück zum Zitat Nakatsu T, Motoyama S, Maruyama K et al (2012) Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg Today 42:652–658CrossRefPubMed Nakatsu T, Motoyama S, Maruyama K et al (2012) Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg Today 42:652–658CrossRefPubMed
29.
Zurück zum Zitat Roth-Isigkeit A, Hasselbach L, Ocklitz E et al (2001) Inter-individual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass. Clin Exp Immunol 125:80–88CrossRefPubMedPubMedCentral Roth-Isigkeit A, Hasselbach L, Ocklitz E et al (2001) Inter-individual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass. Clin Exp Immunol 125:80–88CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Misoph M, Babin-Ebell J (1997) Interindividual variations in cytokine levels following cardiopulmonary bypass. Heart Vessels 12:119–127CrossRefPubMed Misoph M, Babin-Ebell J (1997) Interindividual variations in cytokine levels following cardiopulmonary bypass. Heart Vessels 12:119–127CrossRefPubMed
31.
Zurück zum Zitat Lee Y, Park US, Choi I et al (1998) Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin Cancer Res 4:1711–1717PubMed Lee Y, Park US, Choi I et al (1998) Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin Cancer Res 4:1711–1717PubMed
32.
Zurück zum Zitat Lee YH, Nair S, Rousseau E et al (2005) Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia 48:1776–1783CrossRefPubMedPubMedCentral Lee YH, Nair S, Rousseau E et al (2005) Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia 48:1776–1783CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Nagasaki T, Hara M, Nakanishi H et al (2014) Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 110:469–478CrossRefPubMed Nagasaki T, Hara M, Nakanishi H et al (2014) Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 110:469–478CrossRefPubMed
34.
Zurück zum Zitat Gado K, Domjan G, Hegyesi H et al (2000) Role of interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 24:195–209CrossRefPubMed Gado K, Domjan G, Hegyesi H et al (2000) Role of interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 24:195–209CrossRefPubMed
35.
Zurück zum Zitat Black S, Kushner I, Samols D (2004) C-reactive protein: minireview. J Biol Chem 279:48487–48490CrossRefPubMed Black S, Kushner I, Samols D (2004) C-reactive protein: minireview. J Biol Chem 279:48487–48490CrossRefPubMed
36.
Zurück zum Zitat Sato N, Koeda K, Ikeda K et al (2002) Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg 236:184–190CrossRefPubMedPubMedCentral Sato N, Koeda K, Ikeda K et al (2002) Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg 236:184–190CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Kawahara Y, Ninomiya I, Fujimura T et al (2010) Prospective randomized controlled study on the effects of perioperative administration of a neutrophil elastase inhibitor to patients undergoing video-assisted thoracoscopic surgery for thoracic esophageal cancer. Dis Esophagus 23:329–339CrossRefPubMed Kawahara Y, Ninomiya I, Fujimura T et al (2010) Prospective randomized controlled study on the effects of perioperative administration of a neutrophil elastase inhibitor to patients undergoing video-assisted thoracoscopic surgery for thoracic esophageal cancer. Dis Esophagus 23:329–339CrossRefPubMed
38.
Zurück zum Zitat Wada Y, Yoshida K, Hihara J et al (2006) Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha. Cancer Sci 97:1037–1043CrossRefPubMed Wada Y, Yoshida K, Hihara J et al (2006) Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha. Cancer Sci 97:1037–1043CrossRefPubMed
39.
Zurück zum Zitat Kubota H, Matsumoto H, Higashida M et al (2013) Eicosapentaenoic acid modifies cytokine activity and inhibits cell proliferation in an oesophageal cancer cell line. Anticancer Res 33:4319–4324PubMed Kubota H, Matsumoto H, Higashida M et al (2013) Eicosapentaenoic acid modifies cytokine activity and inhibits cell proliferation in an oesophageal cancer cell line. Anticancer Res 33:4319–4324PubMed
Metadaten
Titel
Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer
verfasst von
Yuta Ibuki
Yoichi Hamai
Jun Hihara
Manabu Emi
Junya Taomoto
Takaoki Furukawa
Ichiko Yamakita
Tomoaki Kurokawa
Morihito Okada
Publikationsdatum
24.01.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 6/2017
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-3900-3

Weitere Artikel der Ausgabe 6/2017

World Journal of Surgery 6/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.